XML 36 R35.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stock-Based Compensation Outstanding Options and SSARs (Details) - Relationship to Entity [Domain] - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 6 Months Ended
Jun. 30, 2015
Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Options / SSARs outstanding at January 1, 2015 7,004  
Incentive shares granted 379  
Options / SSARs exercised (1,141)  
Options / SSARs canceled (281)  
Options / SSARs outstanding at June 30, 2015 5,961  
Options / SSARs outstanding Weighted Average Exercise Price $ 14.32 $ 14.19
Options / SSARs granted Weighted Average Exercise Price 17.04  
Options / SSARs exercised Weighted Average Exercise Price 11.45  
Options / SSARs canceled Weighted Average Exercise Price $ 26.41  
Options / SSARs outstanding Weighted Average Contractual Term (in years) 4 years 8 months 16 days  
Options / SSARs outstanding Aggregate Intrinsic Value (in millions) $ 28.3  
Vested and expected to vest 5,663  
Vested and expected to vest Aggregate Intrinsic Value (in millions) $ 26.9  
Options / SSARs exercisable 5,185  
Options / SSARs exercisable Weighted Average Exercise Price $ 13.78  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term 4 years 26 days  
Options / SSARs exercisable Aggregate Intrinsic Value (in millions) $ 28.3  
Options and SSARs [Member]    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Weighted-average period of years costs are expected to be recognied over 1 year 9 months 18 days  
Compensation Expense $ 1.9  
Unrecognized compensation costs $ 5.7  
Number of Shares Available for Grant 3,900  
Stock Appreciation Rights (SARs) [Member]    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Vesting Period 3 years